Showing results (101-110 of 155) with videos related to
Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumorsChia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.International Journal of Molecular Sciences|February 24, 2024
Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2Lucía Paniagua-Herranz, Irene Moreno, Cristina Nieto-Jiménez, et al.European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.Investigational New Drugs|December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancerJordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.Cancers|October 20, 2020
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF TrialIan Chau, Nicolas Penel, Andres O Soriano, et al.Investigational New Drugs|April 25, 2022
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human studyPatricia LoRusso, Mark J Ratain, Toshihiko Doi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2019
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort ResultsPadmanee Sharma, Arlene Siefker-Radtke, Filippo de Braud, et al.Journal for Immunotherapy of Cancer|March 10, 2021
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancerDavide Melisi, Do-Youn Oh, Antoine Hollebecque, et al.Pageof 16